NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer patients when immunotherapy fails
Disease control Not yet recruitingThis study tests a new combination of two drugs—gemcitabine (a chemotherapy) and ivonescimab (a targeted therapy)—in 47 people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if the combo can shrink tumors and offe…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New hope for lung cancer: experimental drug combo enters final testing phase
Disease control Not yet recruitingThis study tests whether adding an experimental drug called nogapendekin alfa inbakicept (NAI) to standard chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 494 adults with stage IV lung …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for bulky lung cancer: drug plus chemoradiation may slow tumor growth
Disease control Not yet recruitingThis study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with large, stage III lung cancer that can't be surgically removed. About 204 adults aged 18-75 with good performance status will be enrolled. The main goal is to see if the combinatio…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New radiation combo aims to shrink lung tumors faster with less lung damage
Disease control Not yet recruitingThis study tests a new way of giving radiation (high and low doses mixed) along with chemotherapy and immunotherapy before standard treatment for advanced non-small cell lung cancer. The goal is to shrink tumors more quickly and reduce the risk of lung inflammation from radiation…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New plan aims to tame lung cancer treatment side effects
Disease control Not yet recruitingThis study tests a special care plan (CEPM) to help manage side effects like rashes and infusion reactions in people with advanced EGFR-mutated lung cancer taking the drug amivantamab. About 122 Chinese patients will take part. The goal is to see if this plan improves quality of …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE4 • Sponsor: Shanghai Pulmonary Hospital, Shanghai, China • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for lung cancer patients with brain tumors?
Disease control Not yet recruitingThis study tests a new drug combination (Sac-TMT plus a targeted therapy, with or without radiation) in 45 adults with a specific type of lung cancer that has spread to the brain and stopped responding to previous treatment. The goal is to see if this approach can control the can…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for hard-to-treat lung cancer: targeted drug combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug called GFH375, alone or with other medicines, in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. About 90 participants will be split into three groups to see which treatment works best. The goal is to shrink tumo…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New combo therapy aims to stop lung cancer from coming back after surgery
Disease control Not yet recruitingThis study is for people with stage III non-small cell lung cancer who had chemotherapy and immunotherapy before surgery, then surgery to remove the tumor, but still had cancer in their lymph nodes. Researchers want to see if adding targeted radiation to the lymph nodes after sur…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
Lung cancer study aims to decode immune secrets from tiny biopsies
Knowledge-focused Not yet recruitingThis study looks at how the immune system and certain genes affect treatment in people with advanced non-small cell lung cancer. Researchers will collect small tumor samples before and during treatment to study immune markers. The goal is to learn more about why some patients res…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Technische Universität Dresden • Aim: Knowledge-focused
Last updated May 16, 2026 23:53 UTC
-
Can a cancer drug keep working after it fails? new study investigates
Knowledge-focused Not yet recruitingThis study looks at whether the drug anlotinib can still help people with advanced lung cancer even after it has stopped working. Researchers will review medical records from 350 patients with non-small cell or small cell lung cancer. The goal is to see if continuing anlotinib in…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Henan Cancer Hospital • Aim: Knowledge-focused
Last updated May 08, 2026 12:03 UTC